Helen Thackray, M.d., Faap

Biography

Dr. Thackray joined GlycoMimetics in 2006. She has extensive experience in design and execution of pediatric and adult clinical development programs, including early-stage development of novel biologics and small molecules through to successful demonstration of clinical efficacy. In addition, she has a particular interest in Orphan Drug and accelerated regulatory path programs such as Fast Track and Breakthrough Therapy. At GlycoMimetics, she oversees development of investigational products for the company, including clinical programs in sickle cell disease (now in Phase 3 at Pfizer, Inc.), AML (a Breakthrough Therapy program), multiple myeloma, other cancers and thrombosis, and supportive manufacturing and preclinical work. Concurrent to her position at GlycoMimetics, Dr. Thackray holds an appointment as Assistant Clinical Professor of Pediatrics at the George Washington University School of Medicine and is a board-certified hospital-based pediatrician. Previously, she was Vice President of Clinical Product Development at Biosynexus, Inc. While at Biosynexus, Dr. Thackray oversaw the complex clinical development of a biologic product in hospitalized neonates. Prior to entering industry, she completed a pediatrics residency at Children's National Medical Center in Washington, D.C., followed by a year as Pediatric Chief Resident and Adjunct Instructor in Pediatrics. She served as a Medical Genetics Fellow at the National Human Genome Research Institute of the National Institutes of Health. Dr. Thackray received her B.S. from Stanford University and her M.D. from George Washington University School of Medicine. She has served as a member of the Institutional Review Board of the National Center for Healthcare Statistics; served on the BIO PDUFA V Technical Discussions team; and is a Fellow of the American Academy of Pediatrics. 

Research Interest

 Paediatrics, Genomics, Business Management